|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia显示文摘Tumor-induced osteomalacia(TIO) is a rare paraneoplastic syndrome in which ectopic production of fibroblast growth factor 23(FGF23) by non-malignant mesenchymal tumors causes phosphate wasting and bone fractures. Recent studies have implicated the hypoxia-inducible factor-1α(HIF-1α) in other phosphate wasting disorders caused by elevated FGF23, including X-linked hypophosphatemic rickets and autosomal dominant hypophosphatemia. Here we provide evidence that HIF-1α mediates aberrant FGF23 in TIO by transcriptionally activating its promoter. Immunohistochemical studies in phosphaturic mesenchymal tumors resected from patients with documented TIO showed that HIF-1α and FGF23 were co-localized in spindleshaped cells adjacent to blood vessels. Cultured tumor tissue produced high levels of intact FGF23 and demonstrated increased expression of HIF-1α protein. Transfection of MC3T3-E1 and Saos-2 cells with a HIF-1α expression construct induced the activity of a FGF23 reporter construct. Prior treatment of tumor organ cultures with HIF-1α inhibitors decreased HIF-1α and FGF23 protein accumulation and inhibited HIF-1α-induced luciferase reporter activity in transfected cells. Chromatin immunoprecipitation assays confirmed binding to a HIF-1α consensus sequence within the proximal FGF23 promoter, which was eliminated by treatment with a HIF-1α inhibitor. These results show for the first time that HIF-1α is a direct transcriptional activator of FGF23 and suggest that upregulation of HIF-1α activity in TIO contributes to the aberrant FGF23 production in these patients. | Qian Zhang Michele Doucet Ryan E Tomlinson Xiaobin Han L Darryl Quarles Michael T Collins Thomas L Clemens | 2016 | Bone Research2016，4，2： | 6 |
| 2 | Efficacy and safety of liquid nitrogen cryotherapy for treatment of Barrett's esophagus显示文摘AIM To evaluate the efficacy and safety of liquid nitrogen cryotherapy as a primary or rescue treatment for BE,with and without dysplasia,or intramucosal adenocarcinoma (IMC).METHODS This was a retrospective,single-center study carried out in a tertiary care center including 45 patients with BE who was treatment-na?ve or who had persistent intestinal metaplasia(IM),dysplasia,or IMC despite prior therapy.Barrett's mucosa was resected via EMR when clinically appropriate,then patients underwent cryotherapy until eradication or until deemed to have failed treatment.Surveillance biopsies were taken at standard intervals.RESULTS From 2010 through 2014,33 patients were studied regarding the efficacy of cryotherapy.Overall,29 patients (88%) responded to cryotherapy,with 84% having complete regression of all dysplasia and cancer.Complete eradication of cancer and dysplasia was seen in 75% of subjects with IMC; the remaining two subjects did not respond to cryotherapy.Following cryotherapy,15 patients with high-grade dysplasia (HGD) had 30% complete regression,50% IM,and 7% low-grade dysplasia (LGD); one subject had persistent HGD.Complete eradication of dysplasia occurred in all 5 patients with LGD.In 5 patients with IM,complete regression occurred in 4,and IM persisted in one.In 136 cryotherapy sessions amongst 45 patients,adverse events included chest pain (1%),stricture (4%),and one gastrointestinal bleed in a patient on dual antiplatelet therapy who had previously undergone EMR.CONCLUSION Cryotherapy is an efficacious and safe treatment modality for Barrett's esophagus with and without dysplasia or intramucosal adenocarcinoma. | Kristen Suchniak-Mussari Charles E Dye Matthew T Moyer Abraham Mathew Thomas J McGarrity Eileen M Gagliardi Jennifer L Maranki John M Levenick | 2017 | World Journal of Gastrointestinal Endoscopy2017，9，9： | 4 |
| 3 | Critical analysis of feeding jejunostomy following resection of upper gastrointestinal malignancies显示文摘AIM To assess nutritional recovery,particularly regarding feeding jejunostomy tube(FJT)utilization,following upper gastrointestinal resection for malignancy. METHODS A retrospective review was performed of a prospectively-maintained database of adult patients who underwent esophagectomy or gastrectomy(subtotal or total)for cancer with curative intent,from January 2001 to June 2014. Patient demographics,the approach to esophagectomy,the extent of gastrectomy,FJT placement and utilization at discharge,administration of parenteral nutrition(PN),and complications were evaluated. All patients were followed for at least ninety days or until death.RESULTS The 287 patients underwent upper GI resection,comprised of 182 esophagectomy(n=107 transhiatal,58.7%; n=56 Ivor-Lewis,30.7%)and 105 gastrectomy [n=63 subtotal(SG),60.0%; n=42 total(TG),40.0%]. 181 of 182 esophagectomy patients underwent FJT,compared with 47 of 105 gastrectomy patients(99.5% vs 44.8%,P < 0.0001),of whom most had undergone TG(n=39,92.9% vs n=8 SG,12.9%,P < 0.0001). Median length of stay was similar between esophagectomy and gastrectomy groups(14.7 d vs 17.1 d,P=0.076). Upon discharge,87 esophagectomy patients(48.1%)were taking enteral feeds,with 53(29.3%)fully and 34(18.8%)partially dependent. Meanwhile,20 of 39 TG patients(51.3%)were either fully(n=3,7.7%)or partially(n=17,43.6%)dependent on tube feeds,compared with 5 of 8 SG patients(10.6%),all of whom were partially dependent. Gastrectomy patients were significantly less likely to be fully dependent on tube feeds at discharge compared to esophagectomy patients(6.4% vs 29.3%,P=0.0006). PN was administered despite FJT placement more often following gastrectomy than esophagectomy(n=11,23.4% vs n=7,3.9%,P=0.0001). FJT-specific complications requiring reoperation within 30 d of resection occurred more commonly in the gastrectomy group(n=6),all after TG,compared to 1 esophagectomy patient(12.8% vs 0.6%,P=0.0003). Six of 7 patients(85.7%)who experienced tube-related complications required PN.CONCLUSION Nutritional recovery following esophagectomy and gastrectomy is distinct. Operations are associated with unique complication profiles. Nutritional supplementation alternative to jejunostomy should be considered in particular scenarios. | Andrew M Blakely Saad Ajmal Rachel E Sargent Thomas T Ng Thomas J Miner | 2017 | World Journal of Gastrointestinal Surgery2017，9，2： | 4 |
| 4 | Hyperspectral versus multispectral data for estimating leaf area index in four different biomes显示文摘 | Kyu-Sung Lee Warren B Cohen Robert E Kennedy Thomas K Maiersperger Stith T Gower | 2004 | Remote Sensing of Environment2004，，3： | 2 |
| 5 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 6 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 7 | 显示文摘 | Evans E J Thomas I T | 1996 | Biomaterials1996，17，1： | 2 |
| 8 | Predic- tions of urban volumes in single time series显示文摘 | Thomas T Weijermars W Berkum E V | 2010 | IEEE Transactions on Intelligent Transportation Systems2010，11，1： | 1 |
| 9 | Experimental investigation of mineral diesel fuel, GTL fuel, RME and neat soybean and rapeseed oil combustion in a heavy duty on-road engine with exhaust gas after treatment 显示文摘 | PATRIK S DANIEL E THOMAS T | 2009 | Fuel2009，88，1： | 1 |
| 10 | Neoplastic and pro- liferative disorders of the perinephric space显示文摘 | Heller M T Haarer K A Thomas E | 2012 | Clin Radiol2012，67，11： | 1 |
| 11 | Late paleocene to eocene paleocenography of the equatorial pacific ocean: stable isotopes recorded at ocean drilling program site 865, allison guyot显示文摘 | Zachos J C Thomas E Parrow M Paul C K Kelly D C Silva I P Sliter W V Lohmann K C | 1995 | Paleoceanography1995，10，： | 1 |
| 12 | Effects of porcine circovims Type 2 (PCV2) maternal antibodies on experimental infection of piglets with PCV2 clinical and diagnostic laboratory immunology显示文摘 | McKeown N E Opriessnig T Thomas P | 2005 | 12:1 347-1 3512005，12，： | 1 |
| 13 | Persistence, Distribution, and Emission of Telone C35 Injected into a Florida Sandy Soil as Affected by Moisture, Organic Matter, and Plastic Film Cover显示文摘 | THOMAS J E OU L T ALLEN L H | 2004 | J Environ Sci Heal Part B2004，39，4： | 1 |
| 14 | Neodymium isotopic reconstruction of late Paleocene-early Eocene thennohaline eirculation显示文摘 | Thomas D J Bralower T J Jones C E | 2003 | Earth and Planetary Science Letters2003，209，： | 1 |
| 15 | Evidence for downy mildew races incucumber tested in Asia,Europe,and North America显示文摘 | SHETTY N V WEHNER T C THOMAS C E D0RUCH0WSKI RW VASANTH SHETTY K P | 2002 | ScientiaHorticulturae2002，94，3： | 1 |
| 16 | Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase显示文摘 | Aino Soro-Paavonen Wei-Zeng Zhang Kylie Venardos Melinda T Coughlan Emma Harris David CK Tong Daniella Brasacchio Karri Paavonen Jaye Chin-Dusting Mark E Cooper David Kaye Merlin C Thomas Josephine M Forbes | 2010 | Journal of Hypertension2010，，4： | 1 |
| 17 | A genetic linkage map for watermelon derived from a test cross population: (Citrullus lanatusvar, itroides×C, lanatusvar, lanutus)×Citrullus colocynthis Ⅲ 显示文摘 | Levi A Thomas C E Joobeur T | 2002 | Theor Appl Genet2002，105，4： | 1 |
| 18 | Quantitative Patterns of Azathio- prine Adherence after Renal Transplantation显示文摘 | Nevins T E Thomas W | 2009 | Transplan- tation2009，87，5： | 1 |
| 19 | PCR Detects HCV RNA in a plasma pool contaminated by a single preseroconversion donation of Genotype 5a显示文摘 | Branckaert T Mathys E | 2001 | Vox Sang2001，，： | 1 |
| 20 | Type IFNs enhance the terminal differentiation of dendritic cells显示文摘 | Luft T Pang KC Thomas E | 1998 | Immunology1998，161，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员